PriceTargets.com logo

Alterity Therapeutics - ATHE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 200.43%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.33 As of 04/24/2024 01:00 AM ET
▲ +0.2 (9.39%)

This chart shows the closing price for ATHE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alterity Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATHE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATHE

Analyst Price Target is $7.00
▲ +200.43% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Alterity Therapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 200.43% upside from the last price of $2.33.

This chart shows the closing price for ATHE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Alterity Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/7/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$4.00Low
6/5/2023LADENBURG THALM/SH SHLower Target$20.00 ➝ $10.00Low
8/3/2022LADENBURG THALM/SH SHInitiated CoverageBuy$20.00Low
6/23/2022The Goldman Sachs GroupLower TargetNeutral$110.00 ➝ $30.00Low
8/20/2021BenchmarkInitiated CoverageSpeculative Buy$40.00Medium
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Alterity Therapeutics logo
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Read More

Today's Range

Now: $2.33
Low: $2.14
High: $2.50

50 Day Range

MA: $1.94
Low: $1.66
High: $2.94

52 Week Range

Now: $2.33
Low: $1.55
High: $5.41

Volume

172,845 shs

Average Volume

78,211 shs

Market Capitalization

$10.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Alterity Therapeutics?

The following Wall Street research analysts have issued stock ratings on Alterity Therapeutics in the last twelve months: Benchmark Co., and LADENBURG THALM/SH SH.
View the latest analyst ratings for ATHE.

What is the current price target for Alterity Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Alterity Therapeutics in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 200.4%. LADENBURG THALM/SH SH has the highest price target set, predicting ATHE will reach $10.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $4.00 for Alterity Therapeutics in the next year.
View the latest price targets for ATHE.

What is the current consensus analyst rating for Alterity Therapeutics?

Alterity Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATHE will outperform the market and that investors should add to their positions of Alterity Therapeutics.
View the latest ratings for ATHE.

What other companies compete with Alterity Therapeutics?

Other companies that are similar to Alterity Therapeutics include Elevai Labs, Moleculin Biotech, Akari Therapeutics, Guardion Health Sciences and Aeterna Zentaris. Learn More about companies similar to Alterity Therapeutics.

How do I contact Alterity Therapeutics' investor relations team?

Alterity Therapeutics' physical mailing address is LEVEL 3 460 BOURKE STREET, MELBOURNE C3, VIC 3000. The company's listed phone number is (139) 349-4906 and its investor relations email address is [email protected]. The official website for Alterity Therapeutics is www.alteritytherapeutics.com. Learn More about contacing Alterity Therapeutics investor relations.